Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar/Bristol Show Promise With Double IO Combo, But Numbers Are Small

Executive Summary

Updated data from PIVOT-02 at the ASCO GU meeting suggest a path for accelerated approval of the NKTR-214/Opdivo combination as first-line treatment of patients with PD-L1-negative urothelial cancers.

Advertisement

Related Content

Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off
Deals Shaping The Medical Industry, December 2018
US FDA Fine-Tunes Tecentriq, Keytruda First-Line Bladder Cancer Accelerated Approval Indications
A Plea For Patience: Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape
Bristol Goes In Big On New Valentine Nektar

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel